Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

Abstract Background PROMISE-1 and PROMISE-2 evaluated the preventive efficacy, tolerability, and safety of eptinezumab, a calcitonin gene-related peptide–targeted monoclonal antibody, in adults with episodic (EM) and chronic migraine (CM), finding significant reductions in migraine frequency. This p...

Full description

Bibliographic Details
Main Authors: Richard B. Lipton, Larry Charleston, Cristina Tassorelli, Thomas Brevig, Joe Hirman, Roger Cady
Format: Article
Language:English
Published: BMC 2022-02-01
Series:The Journal of Headache and Pain
Subjects:
Eptinezumab
Responder analysis
CGRP monoclonal antibody
Online Access:https://doi.org/10.1186/s10194-022-01386-z

Internet

https://doi.org/10.1186/s10194-022-01386-z

Similar Items